The Effectiveness of the Cabergoline on Preventing the Progression of Prediabetes and Controlling the Insulin Resistance

Introduction: Considering the more prolonged effect of the cabergoline in contrast to bromocriptine along with low complications and also the significance of the central pathway of the glucose metabolism, the high prevalence of obesity and having the metabolic syndrome, it was concluded to estimate the cabergoline effectiveness on preventing the progression of the prediabetes to the type II diabetes. Methods: Two-arm parallel randomized clinical trial was conducted with eighty patients. Patients were treated with the cabergoline for 16 weeks. In the first four weeks, patients received 0.25 mg oral cabergoline twice a week before sleeping, and after that, the cabergoline dosage was increased to 0.5 mg twice a week, and this dosage was continued for 12 weeks. Results and Discussion: cabergoline could significantly reduce the values of Fasting Plasma Glucose (FPG), and 2 h Plasma Glucose (2h-PG) in Oral Glucose Tolerance Tests (OGTT), Hemoglobin A1c (Hb-A1c), Cholesterol, low-density lipoproteins (LDL), 2h-Insulin, Homeostatic Model Assessment for Insulin Resistance (HOMA-IR), Insulin Sensitivity Indices (ISI) Cederholm, ISI Matsuda, and Quantitative Insulin-sensitivity Check Index (QUICKI) tests (p<0.05). Cabergoline did not have any significant effects on the anthropometric parameters including weight, BMI and waist circumference and also, other parameters including Fasting Insulin, High-density lipoproteins (HDL), Atherogenic Factor (LDL / HDL) and Homeostatic Model Assessment of β-cell function (HOMA-β) compared to placebo(p> 0.05). In some of these cases, such as HDL, Fasting Insulin and Atherogenic Factor, the trend of the changes is in favor of the curative effects of cabergoline on the mentioned parameters (p< 0.05). Conclusion: Cabergoline can improve the biochemical factors of the glucose metabolism, and in some other parameters despite having no significant change, it prevented the exacerbation of the disease and led the trend parameter in favor of correcting that parameter.

کلیدواژه ها:

Cabergoline ، Prediabetes ، Glucose metabolism ، Fasting Plasma Glucose